INTRODUCTION
Waldenström macroglobulinemia (WM) is a distinct clinicopathological disease entity showing lymphoplasmacytic lymphoma (LPL) in bone marrow and the IgM monoclonal protein in serum (i.e., macroglobulinemia) at any concentration.
1,2 WM/LPL is characterized by the proliferation of small lymphocytes admixed with variable numbers of plasma cells and plasmacytoid lymphocytes. 2 Patients with WM/ LPL present with a number of symptoms attributable to tumor cell proliferation and/or an excess of macroglobulin. However, macroglobulinemia is observed not only in WM/ LPL, but also a wide range of B-cell lymphoproliferative disorders, including extranodal marginal zone lymphoma (EMZL) of mucosa-associated lymphoid tissue (MALT lymphoma). [3] [4] [5] EMZL/MALT lymphoma is composed of morphologically heterogeneous small B cells and the plasmacytic differentiation of lymphoma cells is common. 4 Thus, the distinction between WM/LPL and EMZL/MALT lymphoma showing plasmacytic differentiation and associated with the serum IgM monoclonal protein is not necessarily clear, even though >90% cases of the former disease have the MYD88 P265P somatic mutation. 2, 6 We herein describe a patient who presented with macroglobulinemia and the accumulation of pleural fluid in the unilateral thoracic cavity. Neoplastic cells in the fluid showed the cytomorphological and immunophenotypic features of plasma cells, indicating the differential diagnosis between WM/LPL and EMZL/MALT lymphoma. Cytogenetic and molecular studies demonstrated a translocation and fusion gene, which was exclusively associated with the latter disease.
Pulmonary extranodal marginal zone lymphoma that presented with macroglobulinemia and marked plasmacytic cell proliferation carrying the t(14;18)(q32;q21)/MALT1-immunoglobulin heavy-chain fusion gene in pleural fluid 
CASE REPORT

Case presentation
An 80-year-old man, who had been treated in another hospital for the recurrent accumulation of pleural fluid in the right thoracic cavity for 2 years, was referred to our department because a cytological examination of the fluid suggested lymphoma cells. On examination, breath sounds were decreased in the right hemithorax. There was no surface lymphadenopathy or hepatosplenomegaly. Oxygen saturation was 96% in room air. A chest radiograph showed prominent pleural effusion ( Figure 1A ). His hemoglobin level was 12.5 g/dL, white blood cell count was 6.95 × 10 3 / μL, and platelet count was 289 × 10 3 /μL. Total serum protein was 6.7 g/dL, albumin 3.2 g/dL, globulin 3. Computed tomography (CT) of the chest revealed the accumulation of pleural fluid in the right thoracic cavity in association with atelectasis of the middle and lower lobes, where the marked accumulation of the tracer was demonstrated by 18 F-fluorodeoxyglucose-positron emission tomography (FDG-PET) combined with CT ( Figure 1B ), suggesting that the atelectatic lesion contained an infiltrative condition.
Thoracentesis yielded exudative fluid containing abundant neoplastic cells with the morphological features of plasma cells at a concentration of 6.13 × 10 3 cells per microliter ( Figure 2A ). These cells expressed IgM/λ monoclonal immunoglobulins both on the cell surface and in the cytoplasm, and showed a wide range of expression levels of CD20, CD22, CD23, CD38, and CD138. CD19 and CD45RA were positive, and CD5, CD10, CD21, CD24, CD56, and surface IgD were negative ( Figures 2B and C) . The DNA index was 1.06 from normal diploid cells. Bone marrow showed hypercellularity containing CD20-positive plasma cells, and flow cytometry revealed a lymphoplasmacytic population with an identical immunophenotype to that of pleural fluid cells. Tests for the MYD88 L265P somatic mutation were negative (Supplementary Figure S1) .
Cytogenetic studies
The G-banding of metaphase spreads obtained from a short-term culture of pleural fluid cells demonstrated numerical and structural abnormalities, including a 14q+ chromosome and uncharacterized small marker chromosome; the karyotype according to the ISCN 2016 was 48,XY,+3,add(9) (p13),+12,add(14)(q32),del (16) Figure S2 ). We then performed hybridization with the MALT1 dual-color, break-apart probe and found that add (14) was marked by the green-labeled telomeric probe, representing 3′ MALT1, while the red-labeled centromeric MALT1 signal was missing, and, accordingly, interphase nuclei showed the one green and two yellow signal pattern ( Figure 3B ). The uncharacterized marker chromosome was marked by unrearranged BCL2 and MALT1 probes, but not of IGH. These cytogenetic studies indicated that the add(14) chromosome represented der(14)t(14;18)(q32;q21), at which the MALT1-IGH fusion gene was localized, while the reciprocal der(18)t(14;18)(q32;q21) was deleted.
Amplification and sequencing of the t(14;18)(q32;q21)/ MALT1-IGH junction
Since the t(14;18)(q32;q21)/MALT1-IGH fusion gene was suggested, DNA extracted from pleural fluid cells was subjected to a long-distance polymerase chain reaction (LD-PCR) in order to amplify the junction encompassing the two genes. PCR primers were designed for MALT1 exon 1 and for the Eμ enhancer as well as the Cμ, Cγ, and Cα constant genes of IGH; the MALT1 probe and IGH probes were oriented in the opposite direction ( Figures 4A and B , Supplementary Table S1 ). As shown in Figure 4C , we obtained LD-PCR products by the MALT1-Eμ and MALT1-Cγ primer combination, indicating Cμ to Cγ class switching. Nucleotide sequencing of the MALT1-Eμ product revealed that the junction occurred at the J6 segment of IGH and the nucleotide position −5,399 of adenine of the ATG start codon of MALT1 at the position +1, and a fragment of 9 base pairs (bp) in length was inserted at the junction ( Figures  4A and D) . As a result of translocation, the MALT1 and IGH Eμ-Cγ segments were aligned in the divergent transcriptional orientation. Reverse-transcriptase PCR confirmed the expression of MALT1 in pleural fluid cells, even though the level was lower than those of in vitro cultured lymphoma cell lines (Supplementary Figure S3) .
We then applied LD-PCR using the MALT1-Eμ primer combination to another case with t(14;18) reported previously by us. 7 The sequences encompassing the MALT1-IGH 
Treatment course
The patient was treated with 6 cycles of the DRP (dexamethasone, rituximab, and cyclophosphamide) regimen every 21 days. 8 This led to the resolution of pleural effusion, the disappearance of lymphoma cell invasion in the bone marrow, and accumulation of the tracer within the lung lesion by FDG-PET/CT. However, the serum IgM/λ M protein remained detectable by immunofixation and the level of serum IgM remained higher than the normal range.
DISCUSSION
We herein described an elderly man who presented with macroglobulinemia and the unilateral accumulation of pleural Since t(14;18)(q32;q21)/MALT1-IGH has been described in a fraction of cases with MALT lymphoma arising in the lung, 4, 11 and because an infiltrative condition of the ipsilateral lung parenchyma was suggested by imaging studies, we propose that this case represents an extreme form of the plasmacytic differentiation of pulmonary EMZL/MALT lymphoma. The plasmacytic differentiation of lymphoma cells in association with or without macroglobulinemia may occur in most small B-cell lymphomas, including WM/LPL, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma (MCL), and EMZL/ MALT lymphoma; however, it varies from being uniformly der (14) 18q21/MALT1 D present, as in WM/LPL, to very uncommon, as in MCL. 6 Furthermore, the extent of plasmacytic differentiation may vary from minimal to very extensive, resulting in a resemblance to plasmacytoma in extreme cases. 4, 6, 12 Thus, plasmacytic differentiation does not define any specific type of small B-cell lymphoma. Since the MYD88 L265P somatic mutation is found in most patients with WM/LPL, it has had a significant impact on the differential diagnosis of small B-cell lymphomas; however, this mutation is not entirely specific to WM/LPL and not required for a diagnosis. 2, 6 In contrast, translocations involving MALT1, BCL10, FOXP1, and GPR34 are exclusively associated with EMZL/MALT lymphoma; 4, 11, 13, 14 therefore, the detection of these translocations by G-banding, FISH, or appropriate molecular methods is of value for a diagnosis. 15 However, the frequencies of each translocation markedly vary with the primary site of disease and not all tumors carry a translocation; the frequency of t(14;18)(q32;q21) in EMZL/MALT lymphoma arising in the lung ranges between 6 and 10%. 4, 11 Thus, cytogenetic/ molecular studies are currently insufficient to effectively discriminate each small B-cell lymphoma category, and the combination of cytomorphological, phenotypic, and sometimes clinical findings is still required in the differential diagnosis of small B-cell lymphomas. t(14;18)(q32.33;q21.32)/MALT1-IGH shares molecular anatomical features with those of t(14;18)(q32.33;q21.33)/ BCL2-IGH, in that both occur at the J segments of IGH, 16 de novo nucleotide additions are identified at both breakpoint junctions, 17, 18 and breakpoints within the BCL2-major breakpoint cluster and MALT1 cluster are in close proximity to CpG. 19 Thus, the two translocations may be mediated by the VDJ recombination process of IGH and the CpG-type double-strand breakage mechanism proposed by Lieber et al., 20 even though, in contrast to the same transcriptional orientation of BCL2-IGH joining, MALT1-IGH joins in the divergent orientation. 16 We herein found that the breakpoint of the present case was positioned at 3.7 kilo-base pairs (kb) upstream of the MALT1 breakpoint cluster, which is located 1.7-kb upstream of the MALT1 start codon, 16, 17, 21 while that of the other case fell within the cluster ( Figure 4A) . Thus, MALT1 breakpoints may not only be clustered, but also distributed outside the cluster, as observed in BCL2 breakpoints. 10 Furthermore, we found that the constant gene was class-switched from Cμ to Cγ, which is another feature frequently observed in the BCL2-IGH fusion gene. 10 Although radiotherapy is a treatment of choice for limited-stage EMZL/MALT lymphoma, single-agent rituximab is generally offered to patients with EMZL/MALT lymphoma primarily arising in the lung, 22 and radiotherapy is avoided because of the long-term morbidity associated with damage to normal lung tissue. The DRC regimen, which is a combination of rituximab and a cytotoxic agent, was initially developed for patients with WM, showing an overall survival rate of 83% and median progression-free survival of 35 months in a phase II trial. 8 Since the present patient responded well to and tolerated the treatment, this regimen may be applied to advanced-stage EMZL/MALT lymphoma.
